Technical Analysis for RAC - Race Oncology Ltd
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Strong but Oversold | Other | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Gapped Up | Strength | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | -1.08% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -1.08% | |
NR7 | Range Contraction | -1.08% | |
Narrow Range Bar | Range Contraction | -1.08% | |
Stochastic Reached Oversold | Weakness | -1.08% | |
Strong but Oversold | Other | -1.08% |
Alert | Time |
---|---|
Down 1% | about 19 hours ago |
Fell Below Previous Day's Low | about 20 hours ago |
Outside Day | about 20 hours ago |
Gap Up Closed | about 20 hours ago |
Reversed from Up | about 20 hours ago |
Get this analysis on your stocks daily!
Race Oncology Ltd Description
Race Oncology Limited, formerly Coronado Resources Limited, is an Australia-based specialty pharmaceutical company whose business model is to pursue and bring to market later stage assets, principally in the cancer field. The Company's Bisantrene drug is a chemotherapy drug, which is related to the anthracyclines, a class of drugs used as the first line of treatment for acute myeloid leukemia (AML) and other cancers. Its Bisantrene drug reduces cardiac toxicity compared to anthracyclines and to be effective against some cancers that have relapsed after the patients have already received high levels of anthracyclines, which makes Bisantrene as a second- or third-line treatment for patients reaching their cardio-toxic limit of anthracyclines or whose cancer has become resistant to anthracycline treatment. It has received orphan drug designation for Bisantrene in the United States. Its clinical opportunity for Bisantrene is used as a salvage treatment for elderly patients with AML.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Cancer Drugs Clinical Medicine Cancers Therapy Oncology Chemotherapy Isan Leukemia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.97 |
52 Week Low | 0.64 |
Average Volume | 157,822 |
200-Day Moving Average | 1.008 |
50-Day Moving Average | 1.169 |
20-Day Moving Average | 1.474 |
10-Day Moving Average | 1.499 |
Average True Range | 0.098 |
RSI (14) | 48.72 |
ADX | 48.98 |
+DI | 32.140 |
-DI | 17.864 |
Chandelier Exit (Long, 3 ATRs) | 1.447 |
Chandelier Exit (Short, 3 ATRs) | 1.578 |
Upper Bollinger Bands | 1.662 |
Lower Bollinger Band | 1.286 |
Percent B (%b) | 0.22 |
BandWidth | 25.536 |
MACD Line | 0.062 |
MACD Signal Line | 0.105 |
MACD Histogram | -0.0437 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.490 | ||||
Resistance 3 (R3) | 1.503 | 1.477 | 1.470 | ||
Resistance 2 (R2) | 1.477 | 1.446 | 1.470 | 1.463 | |
Resistance 1 (R1) | 1.423 | 1.427 | 1.410 | 1.410 | 1.457 |
Pivot Point | 1.397 | 1.397 | 1.390 | 1.390 | 1.397 |
Support 1 (S1) | 1.343 | 1.366 | 1.330 | 1.330 | 1.283 |
Support 2 (S2) | 1.317 | 1.347 | 1.310 | 1.277 | |
Support 3 (S3) | 1.263 | 1.317 | 1.270 | ||
Support 4 (S4) | 1.250 |